General Investor Information EBR Systems, page-215

I happened to be reading a thread for IMUGENE (the cancer killing company). A poster today wondered why JP Morgan Australia seems to have disposed of their holdings in IMU. And I thought “maybe to buy EBR shares”. Well they have, haven’t they? We have a clear pipeline to commercialisation, and a relatively easy to understand product with no competition in their category. Whereas IMU are relying on big pharma to make an offer, we already know EBR will target 45 practices that participated in the trials, aiming for 6 sales each for $US 35000 in their first year after FDA Approval. We can assume 100% growth. I found a fun way to estimate a share’s intrinsic value see https://www.omnicalculator.com/finance/intrinsic-value
Assuming funds compete with a corporate bond rate of 4%, EBR’s shares will have an intrinsic value of $7.06 in their first year of trading. Ok so I didn’t allow for costs in the earnings per share field, but still I used US dollars so that should compensate!

As they say in the classics, do your own research.